Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Biomea Fusion, Inc.

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
Biomea Fusion Reports Second Quarter 2024 Financial Results and Corporate Highlights
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
Biomea Fusion Announces BMF-219 in Diabetes Placed on Clinical Hold
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
Biomea Fusion Announces Completion of Enrollment of First 3 Arms in Phase 2 Expansion Cohorts of COVALENT-111 Study for BMF-219 in Type 2 Diabetes
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
Biomea Fusion Reports First Quarter 2024 Financial Results and Corporate Highlights
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219’s 28-Day Treatment Cycle, Supporting Improved Pancreatic Function
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
Biomea Fusion Highlights Recent Updates and Anticipated 2024 Corporate Milestones at 42nd Annual J.P. Morgan Healthcare Conference
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase II Study (COVALENT-112) with BMF-219
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
Biomea Fusion to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
Biomea Fusion Presents Achievement of Minimal Residual Disease Negativity (MRD-neg) in First Complete Responder from Ongoing Phase I Study (COVALENT-101) of BMF-219 in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) at the 2023 ASH
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
Biomea Fusion Announces Near Doubling the Percentage of Patients with Durable HbA1c Reduction in the 200 mg Dose Cohorts
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
Biomea Fusion Presents Long-Term Follow-Up Data Showing Improved Glycemic Control after 22 Weeks Off Treatment in Ongoing Phase II Study (COVALENT-111) of BMF-219 in Adults with Type 2 Diabetes in a Poster Presentation at the World Congress Insulin
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
Biomea Fusion to Present Long-Term Follow-Up Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Adults with Type 2 Diabetes and Results from Ex-Vivo Human Islet Experiments at the World Congress Insulin Resistance, Diabetes & Cardiovascular
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
Biomea Fusion Announces Health Canada Clearance of Clinical Trial Application (CTA) for BMF-219 in Type 1 Diabetes
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
Biomea Fusion Announces Acceptance of Three Abstracts for its Novel Menin Inhibitor Highlighting Durable Glycemic Control in Diabetes Patients at the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in 2024
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
Biomea Fusion Abstract “BMF-219: A Novel Therapeutic Agent to Reestablish Functional Beta Cells and Provide Long-term Glycemic Control" Selected as One of Six Oral Presentations at 21st World Congress Insulin Resistance, Diabetes & Cardiovascular Disease
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
Biomea Fusion to Present New Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
Biomea Fusion Announces Two Poster Presentations at Upcoming ASH Annual Meeting 2023
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
Biomea Fusion Reports Third Quarter 2023 Financial Results and Corporate Highlights
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
Biomea Fusion Announces First Patient Dosed with Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia in Phase I Clinical Trial (COVALENT-103)
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for BMF-219 in Type 1 Diabetes
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
Biomea Fusion Announces FDA and Health Canada Clearance of the Expansion Cohorts of the Ongoing COVALENT-111 Phase II Study
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
Biomea Fusion Announces Appointment of Juan Pablo Frías, M.D. as Chief Medical Officer
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
Biomea Fusion Reports Second Quarter 2023 Financial Results and Corporate Highlights
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.